Strategies to Prevent Acute Kidney Injury after Pediatric Cardiac Surgery

Strategies to Prevent Acute Kidney Injury after Pediatric Cardiac Surgery

Abstract

Background and objectives AKI is a common complication after pediatric cardiac surgery and has been associated with higher morbidity and mortality. We aimed to compare the efficacy of available pharmacologic and nonpharmacologic strategies to prevent AKI after pediatric cardiac surgery.

Design, setting, participants, & measurements PubMed/MEDLINE, Embase, Cochrane Controlled Trials Register, and reference lists of relevant articles were searched for randomized controlled trials from inception until August 2020. Random effects traditional pairwise, Bayesian network meta-analyses, and trial sequential analyses were performed.

Results Twenty randomized controlled trials including 2339 patients and 11 preventive strategies met the eligibility criteria. No overall significant differences were observed compared with control for corticosteroids, fenoldopam, hydroxyethyl starch, or remote ischemic preconditioning in traditional pairwise meta-analysis. In contrast, trial sequential analysis suggested a 80% relative risk reduction with dexmedetomidine and evidence of <57% relative risk reduction with remote ischemic preconditioning. Nonetheless, the network meta-analysis was unable to demonstrate any significant differences among the examined treatments, including also acetaminophen, aminophylline, levosimendan, milrinone, and normothermic cardiopulmonary bypass. Surface under the cumulative ranking curve probabilities showed that milrinone (76%) was most likely to result in the lowest risk of AKI, followed by dexmedetomidine (70%), levosimendan (70%), aminophylline (59%), normothermic cardiopulmonary bypass (57%), and remote ischemic preconditioning (55%), although all showing important overlap.

Conclusions Current evidence from randomized controlled trials does not support the efficacy of most strategies to prevent AKI in the pediatric population, apart from limited evidence for dexmedetomidine and remote ischemic preconditioning.

Recent Stories
FREE: The Case for the Anesthesiologist-Informaticist.

FREE: Robotic Cardiac Surgery in Europe: Status 2020.

FREE: Efficacy of Prothrombin Complex Concentrate (PCC) versus Fresh Frozen Plasma (FFP) in Reducing Perioperative Blood Loss in Cardiac Surgery: Study Protocol for A Non-Inferiority, Randomised Controlled Trial.

AmSECT Membership Eligibility

An Active Member shall be any perfusionist active in the practice of extracorporeal circulation technology. There are also opportunities to become a Transitional Active Member for those less than a year removed from graduation from an approved accredited training program. Other options include; an Associate Membership, International Membership, Perioperative Blood Management Clinician Membership, and Student Membership.

Click Here to Learn More

Looking for Employment Opportunities?

AmSECT members may post an available position for a perfusion specialty at your institution or firm.

Non-members may also post positions free of charge, to be reviewed by National Headquarters prior to posting.

Members - Click to Post a Position
Non-Members - Click to Post a Position

Contact AmSECT


AmSECT National Headquarters
330 N Wabash Ave, Suite 2000
Chicago, IL 60611

  Phone: (312) 321-5156
  Fax: (312) 673-6656
  Email: amsect@amsect.org

AmSECT © 2022 | View Privacy Policy | Site Map